Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Shasun Move Into Japan Signals Changing Attitudes Toward API Makers

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers are the target of a major effort by India's Shasun Chemicals and Drugs to have a large presence as a supplier of active pharmaceutical ingredients. Shasun is a leading producer of APIs and intermediaries and the world's leading maker of ibuprofen. The firm is a major supplier to leading Western drug makers, but has not had much of a presence in Japan because its pharmas tended not to outsource such work. The economic climate is leading many Japanese firms to rethink that policy as a way to cut costs. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072608

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel